Travelan® Sales Up 76% in North America Drives Immuron’s A$7.3m FY25 Revenue
Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.
- FY25 global sales revenue up 49% to A$7.3 million
- North American Travelan® sales surged 76%
- ProIBS product launch planned for Q1 2026 in Australia
- Key clinical milestones – Travelan® FDA meeting and IMM-529 IND submission/approval
- Increased marketing investment alongside stable hyperimmune product profits
Strong Sales Momentum
Immuron Ltd (ASX, IMC, NASDAQ, IMRN) has delivered a compelling FY25 performance, with global sales revenue reaching A$7.3 million, marking a 49% increase over the previous year. This growth was largely propelled by Travelan®, the company’s flagship oral immunotherapeutic targeting traveller’s diarrhoea, which saw particularly strong uptake in North America where sales jumped 76% to A$2.0 million.
In Australia, Travelan® sales rose 40%, supported by expanded pharmacy distribution agreements that now include nine additional banner groups. The company’s commercial footprint spans thousands of pharmacies across Australia, Canada, and the US, underpinning its growing market presence.
Clinical Pipeline Progress
Beyond commercial success, Immuron is advancing its clinical pipeline with several key milestones on the horizon. The Uniformed Services University trial for Travelan® has completed recruitment and randomization of 866 participants, with topline results expected in October 2025. These data will inform an anticipated End of Phase 2 meeting with the FDA in the first half of 2026, a critical regulatory step for the product’s US development.
Meanwhile, IMM-529, targeting Clostridioides difficile infection, is preparing for an Investigational New Drug (IND) submission to the FDA by the end of September 2025, with approval expected by December. This positions Immuron to potentially expand its therapeutic reach into a significant infectious disease market.
Upcoming Product Launch and Strategic Investments
Immuron is also gearing up for the Australian launch of ProIBS, a treatment for irritable bowel syndrome symptoms, anticipated in the first quarter of calendar year 2026. The company has already secured initial stock orders, signaling confidence in market demand.
Despite stable profits from hyperimmune products at A$1.35 million, Immuron has increased its selling and marketing expenditure by A$1.4 million in FY25, reflecting a strategic push to accelerate growth and market penetration.
Financial Position and Outlook
Immuron’s cash and term deposits stood at A$5.9 million as of June 30, 2025, excluding an additional A$2.8 million raised through a US placement in July. The company reported an EBITDA loss (excluding R&D) of A$3.1 million, though this represented a A$2.1 million improvement year-on-year, indicating operational progress alongside investment in growth.
Looking ahead, Immuron’s blend of commercial momentum, clinical advancement, and strategic product launches sets the stage for a potentially transformative period. Investors will be watching closely for the October clinical data readout and the FDA’s response to the IMM-529 IND submission, both pivotal for validating the company’s development trajectory.
Bottom Line?
Immuron’s FY25 growth and upcoming clinical milestones position it at a critical inflection point for market expansion and regulatory validation.
Questions in the middle?
- Will Travelan®’s October trial results meet expectations to secure FDA Phase 2 progression?
- How will the FDA’s decision on IMM-529’s IND impact Immuron’s infectious disease portfolio?
- What market reception can be expected for ProIBS upon its Australian launch in early 2026?
